Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven stage IV colorectal carcinoma.~* Failed or refused conventional chemotherapy.~* Lewis Y antigen present on more than 50% of tumor cells.~* Measurable or evaluable disease.~* No central nervous system (CNS) tumor involvement.~* Karnofsky 80-100%.~* Life expectancy: At least 6 weeks.~* Granulocyte count greater than 1,500/mm\^3.~* Platelet count greater than 100,000/mm\^3.~* Bilirubin no greater than 1.0 mg/dL.~* Prothrombin time less than 3 times upper limit of normal.~* Creatinine no greater than 1.4 mg/dL.~* Female patients of childbearing age and male patients must be asked to use effective contraception during the study.~* At least 4 weeks since other prior immunotherapy. Exclusion Criteria~* New York Heart Association class III or IV heart disease.~* Serious infection requiring antibiotics or other serious illness.~* Pregnancy or nursing.~* History of bleeding gastric ulcers or pancreatitis.~* Diabetes mellitus requiring insulin.~* Human antimouse antibodies (HAMA).~* No prior mouse monoclonal antibody or antibody fragments.~* Illness requiring the use of steroids or other anti-inflammatory agents.~* Positive anti-hu3S193 antibody (HAHA) titer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hu3S193 10 mg/m2 (Type: EXPERIMENTAL): Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
- Hu3S193 25 mg/m2 (Type: EXPERIMENTAL): Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
- Hu3S193 50 mg/m2 (Type: EXPERIMENTAL): Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
- Hu3S193 100 mg/m2 (Type: EXPERIMENTAL): Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
- Hu3S193 200 mg/m2 (Type: EXPERIMENTAL): Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).